DE60009931D1 - Muscarin-antagonisten - Google Patents

Muscarin-antagonisten

Info

Publication number
DE60009931D1
DE60009931D1 DE60009931T DE60009931T DE60009931D1 DE 60009931 D1 DE60009931 D1 DE 60009931D1 DE 60009931 T DE60009931 T DE 60009931T DE 60009931 T DE60009931 T DE 60009931T DE 60009931 D1 DE60009931 D1 DE 60009931D1
Authority
DE
Germany
Prior art keywords
muscarinic antagonists
muscarinic
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60009931T
Other languages
English (en)
Other versions
DE60009931T2 (de
Inventor
W Clader
A Kozlowski
W Mccombie
W Miller
F Vice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE60009931D1 publication Critical patent/DE60009931D1/de
Application granted granted Critical
Publication of DE60009931T2 publication Critical patent/DE60009931T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
DE60009931T 1999-09-22 2000-07-05 Muscarin-antagonisten Expired - Lifetime DE60009931T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40139199A 1999-09-22 1999-09-22
US401391 1999-09-22
PCT/US2000/018358 WO2001021590A1 (en) 1999-09-22 2000-07-05 Muscarinic antagonists

Publications (2)

Publication Number Publication Date
DE60009931D1 true DE60009931D1 (de) 2004-05-19
DE60009931T2 DE60009931T2 (de) 2005-04-07

Family

ID=23587566

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60009931T Expired - Lifetime DE60009931T2 (de) 1999-09-22 2000-07-05 Muscarin-antagonisten

Country Status (14)

Country Link
EP (1) EP1214299B1 (de)
JP (1) JP2003509494A (de)
CN (1) CN1167682C (de)
AR (1) AR025459A1 (de)
AT (1) ATE264301T1 (de)
AU (1) AU5786300A (de)
CA (1) CA2384018C (de)
CO (1) CO5180624A1 (de)
DE (1) DE60009931T2 (de)
ES (1) ES2215055T3 (de)
HK (1) HK1043590A1 (de)
MX (1) MXPA02003136A (de)
PE (1) PE20010649A1 (de)
WO (1) WO2001021590A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
JP2005506339A (ja) * 2001-10-10 2005-03-03 シェーリング　コーポレイション ムスカリン性アンタゴニストとしてのピペリジン化合物
WO2004069828A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CA3001873A1 (en) * 2015-11-06 2017-05-11 Neurocrine Biosciences, Inc. N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurologicaldiseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
TW474933B (en) * 1998-06-30 2002-02-01 Schering Corp Muscarinic antagonists

Also Published As

Publication number Publication date
AR025459A1 (es) 2002-11-27
CA2384018A1 (en) 2001-03-29
CO5180624A1 (es) 2002-07-30
ATE264301T1 (de) 2004-04-15
CA2384018C (en) 2010-01-12
ES2215055T3 (es) 2004-10-01
PE20010649A1 (es) 2001-06-19
DE60009931T2 (de) 2005-04-07
EP1214299B1 (de) 2004-04-14
WO2001021590A1 (en) 2001-03-29
EP1214299A1 (de) 2002-06-19
MXPA02003136A (es) 2002-09-30
JP2003509494A (ja) 2003-03-11
HK1043590A1 (zh) 2002-09-20
CN1374949A (zh) 2002-10-16
AU5786300A (en) 2001-04-24
CN1167682C (zh) 2004-09-22

Similar Documents

Publication Publication Date Title
DE60139571D1 (de) Muscarin-antagonisten
DE60026169D1 (de) Selektive neurokinin-antagonisten
NO20016115L (no) Substituerte heterosykelkondenserte gamma-karbolin
PT1224180E (pt) Azois substituidos
ID26447A (id) Turunan eritropoietin
DE19983871T1 (de) Fönvorrichtung
DE10084676T1 (de) Einmallanzettvorrichtung
ATA51899A (de) Handstempel
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
NO20015779D0 (no) Bradykinin-reseptorantagonister
ID30214A (id) Turunan resorsinol
DE60009931D1 (de) Muscarin-antagonisten
NO20015237L (no) Integrinreseptor-antagonister
DE19983890T1 (de) Ventiltaktgebungsjustiereinrichtung
DE60015576D1 (de) 4-fluoroalkyl-3-halophenyl nortropane
NO20022927D0 (no) Substituerte pyrrazoler
DE60037169D1 (de) Chrominanzsignalinterpolation
DE10082008D2 (de) Ausbeulgerät
DE50003921D1 (de) Substituierte phenyluracile
ATE440824T1 (de) Nitro-sulfobenzamide
ATA107599A (de) Heizwasserbereiter
DE29903731U1 (de) Geländer
NO992248D0 (no) Rekkverk
AT500658A3 (de) Isolierplatte

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition